Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 2020-03-31
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Klarisens 10mg Orodispersible Tablet is indicated for the symptomatic treatment of allergic rhinitis (AR) and chronic idiopathic urticaria (CIU).
Adults and children over 12 years of age
10 mg once daily (one orodispersible tablet once daily).
Children 2 to 12 years of age with body weight more than 30 kg: 10 mg once daily (one orodispersible tablet once daily).
The 10 mg strength orodispersible tablet is not appropriate in children with a body weight less than 30 kg.
Efficacy and safety of Klarisens in children under 2 years of age has not been established.
Patients with hepatic impairment
Patients with severe hepatic impairment should be administered a lower initial dose because they may have reduced clearance of Klarisens. An initial dose of 10 mg every other day is recommended for adults and children weighing more than 30 kg.
Patients with renal impairment
No dosage adjustments are required in patients with renal insufficiency.
No dosage adjustments are required in the elderly.
Method of administration
Klarisens 10 mg orodispersible tablets should be handled with caution and with dry hands only.
Klarisens 10 mg orodispersible tablets are intended for oral use.
The tablet shall be put on the tongue and wait until it is thoroughly disintegrated. Water or other liquid is not needed to swallow the dose.
The orodispersible tablet may be taken without regard to mealtime.
Klarisens 10 mg orodispersible tablets are contraindicated in patients who are hypersensitive to the active substance or to any of the excipients in these formulations.
Klarisens should be administered with caution in patients with severe hepatic impairment.
This product contains lactose and sorbitol. Patients with rare hereditary problems of fructose intolerance, galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This product contains aspartame. Aspartame is a source of phenylalanine, which may be harmful for people with phenylketonuria.
The administration of Klarisens should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.
In clinical trials that assessed driving ability, no impairment occurred in patients receiving Klarisens. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.
Adverse events which have been associated with Klarisens are given below. Frequencies are defined as:
Very common (>1/10)
Common (>1/100 to <1/10)
Uncommon (>1/1,000 to <1/100)
Rare (>1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data).
In clinical trials in a paediatric population, children aged 2 through 12 years, common adverse reactions reported in excess of placebo were headache (2.7%), nervousness (2.3%), and fatigue (1%).
In clinical trials involving adults and adolescents in a range of indications including AR and CIU, at the recommended dose of 10 mg daily, adverse reactions with Klarisens were reported in 2 % of patients in excess of those treated with placebo.
The most frequent adverse reactions reported in excess of placebo were somnolence (1.2%), headache (0.6%), increased appetite (0.5%) and insomnia (0.1%).
Other adverse reactions reported during the post-marketing period are listed in the following table.
Immune system disorders
Hypersensitivity reactions (including angioedema and anaphylaxis)
Nervous system disorders
Nausea, dry mouth, gastritis
Abnormal hepatic function
Skin and subcutaneous tissue disorders
General disorders and administration site conditions
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdosage with Klarisens increased the occurrence of anticholinergic symptoms. Somnolence, tachycardia, and headache have been reported with overdoses.
In the event of overdose, general symptomatic and supportive measures are to be instituted and maintained for as long as necessary. Administration of activated charcoal as a slurry with water may be attempted. Gastric lavage may be considered. Klarisens is not removed by haemodialysis and it is not known if Klarisens is removed by peritoneal dialysis. Medical monitoring of the patient is to be continued after emergency treatment.
Pharmacotherapeutic group: antihistamines - H1 antagonist, ATC code: R06A X13.
Mechanism of action
Klarisens, the active ingredient in the medicinal product, is a tricyclic antihistamine with selective, peripheral Hl-receptor activity.
Klarisens has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage.
During long-term treatment there were no clinically significant changes in vital signs, laboratory test values, physical examinations or electrocardiograms.
Klarisens has no significant H2-receptor activity. It does not inhibit norepinephrine uptake and has practically no influence on cardiovascular function or on intrinsic cardiac pacemaker activity.
Klarisens is rapidly and well absorbed. Concomitant ingestion of food can delay slightly the absorption of Klarisens but without influencing the clinical effect.
Klarisens is highly bound (97 % to 99 %) and its active metabolite moderately bound (73 % to 76 %) to plasma proteins.
In healthy subjects, plasma distribution half-lives of Klarisens and its active metabolite are approximately 1 and 2 hours, respectively.
After oral administration, Klarisens is rapidly and well absorbed and undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite -desKlarisens (DL)- is pharmacologically active and responsible for a large part of the clinical effect. Klarisens and DL achieve maximum plasma concentrations (Tmax) between 1-1.5 hours and 1.5-3.7 hours after administration, respectively.
Increase in plasma concentrations of Klarisens has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).
The mean elimination half-lives in healthy adult subjects were 8.4 hours (range = 3 to 20 hours) for Klarisens and 28 hours (range = 8.8 to 92 hours) for the major active metabolite.
Approximately 40 % of the dose is excreted in the urine and 42 % in the faeces over a 10 day period and mainly in the form of conjugated metabolites. Approximately 27 % of the dose is eliminated in the urine during the first 24 hours. Less than 1 % of the active substance is excreted unchanged in active form, as Klarisens or DL.
The bioavailability parameters of Klarisens and of the active metabolite are dose proportional.
The pharmacokinetic profile of Klarisens and its metabolites is comparable in healthy adult volunteers and in healthy geriatric volunteers.
In patients with chronic renal impairment, both the AUC and peak plasma levels (Cmax) increased for Klarisens and its metabolite as compared to the AUCs and peak plasma levels (Cmax) of patients with normal renal function. The mean elimination half-lives of Klarisens and its metabolite were not significantly different from that observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of Klarisens or its active metabolite in subjects with chronic renal impairment.
In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (Cmax) of Klarisens were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function. The elimination half-lives for Klarisens and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease.
Klarisens and its active metabolite are excreted in the breast milk of lactating women.
Preclinical data reveal no special hazard based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.
In reproductive toxicity studies, no teratogenic effects were observed. However, prolonged parturition and reduced viability of offspring were observed in rats at plasma levels (AUC) 10 times higher than those achieved with clinical doses.
No evidence of mucous membrane irritation was observed after daily administration of up to 12 tablets (120 mg) of oral lyophilisates into the hamster cheek pouch for five days.
No special requirements.
However, we will provide data for each active ingredient